Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Cerulean Pharma (CERU) seeking strategic alternatives

  • February 21, 2017

Cerulean Pharma (CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that its Board of Directors is conducting a comprehensive review of strategic alternatives focused on maximizing stockholder value. Cerulean has engaged investment bank, Aquilo Partners, L.P., as its financial advisor to assist in the strategic review process.

The intention of the strategic review is to evaluate potential alternatives such as the sale of the company, a merger, a business combination, a strategic investment into the company, or a sale, license or disposition of assets of the company. This process may not result in any transaction.


July 19, 2017: Cerulean Pharma Inc.  (CERU) and Daré Bioscience Operations, Inc. (formerly Daré Bioscience, Inc.) today announced the closing of the transactions contemplated by the stock purchase agreement entered into by the companies on March 19, 2017